Chugai Pharmaceutical Co., Ltd. provided consolidated non-audited earnings guidance for the financial year 2024. For the year, company expects revenues of JPY 1,070,000 million, Core operating profit of JPY 460,000 million, Core net income of JPY 335,500 million and Core earnings per share of JPY 204.00.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4,852 JPY | -0.16% | -1.40% | -9.17% |
Apr. 25 | Chugai Pharmaceutical's Parent Roche Logs Lower Q1 Sales; Stock Falls 5% | MT |
Apr. 24 | Chugai Pharmaceutical's Profit Slightly Up in Q1 | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-9.17% | 50.71B | |
+25.83% | 661B | |
+27.00% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+13.09% | 231B | |
+5.46% | 200B | |
-9.61% | 195B | |
-6.26% | 145B |
- Stock Market
- Equities
- 4519 Stock
- News Chugai Pharmaceutical Co., Ltd
- Chugai Pharmaceutical Co., Ltd. Provides Consolidated Non-Audited Earnings Guidance for the Financial Year 2024